Search
Rheumatoid Arthritis Clinical Trials
A listing of 57 Rheumatoid Arthritis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 57
There are currently 57 active clinical trials seeking participants for Rheumatoid Arthritis research studies. The states with the highest number of trials for Rheumatoid Arthritis participants are Florida, California, Texas and Pennsylvania.
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Chronic Obstructive Pulmonary Disease Study
Recruiting
Conditions:
Lung Disease (COPD)
Smoker
Featured Trial
Systemic Sclerosis Associated Interstitial Lung Disease Study
Recruiting
Conditions:
Scleroderma
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Christine Thai, MD, Huntington Beach, California +47 locations
Conditions: Rheumatoid Arthritis
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Recruiting
This is a 16-week, open-label study to identify factors that help predict clinical responses to disease-modifying antirheumatic drugs (DMARD) therapies for rheumatoid arthritis (RA) patients. All patients will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is determ... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
06/19/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Rheumatoid Arthritis
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Recruiting
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive.
Study tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Inland Rheumatology Clinical Trials, Inc. Site Number : 8400004, Upland, California +68 locations
Conditions: Rheumatoid Arthritis
Early Rheumatoid Arthritis Lung Disease Study
Recruiting
The primary goal of this study is to investigate lung disease, through pulmonary function and high resolution chest CT, in newly diagnosed rheumatoid arthritis (RA) patients. Extra-articular disease occurs in approximately 50% of RA patients, with the lung being a common site of involvement.
Investigators goal is to understand the prevalence of lung disease in early RA patients and to better characterize it through questionnaires, imaging, and serum studies. Additionally, the goal is to find no... Read More
Gender:
All
Ages:
Between 19 years and 90 years
Trial Updated:
06/19/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Rheumatoid Arthritis
Actis Total Hip System 2 Year Follow-up
Recruiting
Two-year (2 year) information regarding the performance of the commercially available Actis™ Total Hip System in order to obtain and evaluate the clinical outcomes on a series of cementless primary total hip arthroplasty (THA) and hemi-hip arthroplasty procedures using clinical, radiographic and device and procedure related adverse event assessments.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/18/2024
Locations: Not set, Louisville, Kentucky +9 locations
Conditions: Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of the Femoral Head, Acute Traumatic Fracture of the Femoral Head or Neck, Certain Cases of Ankylosis, Non-union of Femoral Neck Fractures, Certain High Sub-Capital & Femoral Neck Fractures in Elderly
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Denver Hip & Knee, Inc., Parker, Colorado +16 locations
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed.
Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona +197 locations
Conditions: Rheumatoid Arthritis
Pain Processing in Inflammatory and Non-Inflammatory Chronic Pain Syndromes
Recruiting
Fibromyalgia (FM) is a chronic musculoskeletal pain disorder that afflicts up to 4% of the general population. The evaluation of pain mechanisms in FM has shown predominant central abnormalities and therefore has been designated as nociplastic pain syndrome. Rheumatoid arthritis (RA) is characterized by polyarthritis and pain from inflamed tissues, consistent with nociceptive pain. FM and RA patients may utilize overlapping pain mechanisms resulting in nociceptive and nociplastic pain.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/14/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Fibromyalgia, Rheumatoid Arthritis
Study of GS-0272 in Participants With Rheumatoid Arthritis
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA).
The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: Clinical Research of West Florida, Inc., Clearwater, Florida +4 locations
Conditions: Rheumatoid Arthritis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +50 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
Recruiting
Background:
Inflammation can play a role in diseases like heart disease and rheumatoid arthritis. PET scans can help detect inflammation. Two new drugs may create better PET images.
Objective:
To see if the drugs [11C]ER176 and [11C]MC1 can help image inflammation.
Eligibility:
People ages 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM).
Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed.
Design:
Healthy participants will be sc... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: East Alabama Arthritis Center PC, Auburn, Alabama +48 locations
Conditions: Rheumatoid Arthritis
1 - 12 of 57